JP2021518397A5 - - Google Patents
Info
- Publication number
- JP2021518397A5 JP2021518397A5 JP2020550674A JP2020550674A JP2021518397A5 JP 2021518397 A5 JP2021518397 A5 JP 2021518397A5 JP 2020550674 A JP2020550674 A JP 2020550674A JP 2020550674 A JP2020550674 A JP 2020550674A JP 2021518397 A5 JP2021518397 A5 JP 2021518397A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- pharmaceutical composition
- composition according
- recurrent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024052953A JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647346P | 2018-03-23 | 2018-03-23 | |
| US62/647,346 | 2018-03-23 | ||
| US201862658276P | 2018-04-16 | 2018-04-16 | |
| US62/658,276 | 2018-04-16 | ||
| PCT/US2019/023516 WO2019183438A1 (en) | 2018-03-23 | 2019-03-22 | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024052953A Division JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021518397A JP2021518397A (ja) | 2021-08-02 |
| JP2021518397A5 true JP2021518397A5 (https=) | 2022-03-30 |
Family
ID=66041744
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550674A Pending JP2021518397A (ja) | 2018-03-23 | 2019-03-22 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
| JP2024052953A Pending JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024052953A Pending JP2024075771A (ja) | 2018-03-23 | 2024-03-28 | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190290775A1 (https=) |
| EP (1) | EP3768714A1 (https=) |
| JP (2) | JP2021518397A (https=) |
| KR (1) | KR20200135841A (https=) |
| CN (1) | CN112189020A (https=) |
| AU (1) | AU2019240403A1 (https=) |
| BR (1) | BR112020018948A2 (https=) |
| CA (1) | CA3093731A1 (https=) |
| IL (1) | IL277338A (https=) |
| MA (1) | MA52135A (https=) |
| MX (1) | MX2020009842A (https=) |
| SG (1) | SG11202009264WA (https=) |
| TW (1) | TW202003047A (https=) |
| WO (1) | WO2019183438A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019392090A1 (en) | 2018-12-03 | 2021-06-17 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| EP4148070A4 (en) * | 2020-05-03 | 2024-04-24 | Shanghai Miracogen Inc. | Antibody-drug conjugate and preparation thereof |
| MX2022016232A (es) * | 2020-06-19 | 2023-03-14 | Agensys Inc | Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc). |
| TW202229346A (zh) * | 2020-09-28 | 2022-08-01 | 美商西根公司 | 用於治療癌症之人化抗ｌｉｖ１抗體 |
| BR112023018676A2 (pt) | 2021-03-18 | 2023-10-10 | Seagen Inc | Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco |
| MX2024005080A (es) | 2021-10-29 | 2024-05-13 | Seagen Inc | Metodos para tratar cancer con una combinacion de un anticuerpo anti-pd-1 y un conjugado de anticuerpo anti-cd30-farmaco. |
| AU2024228349A1 (en) * | 2023-02-27 | 2025-09-11 | CSPC Megalith Biopharmaceutical Co., Ltd. | Pharmaceutical composition of recombinant humanized anti-nectin-4 monoclonal antibody-mmae conjugate drug |
| JP2026508672A (ja) * | 2023-03-17 | 2026-03-11 | ザイダス・ライフサイエンシーズ・リミテッド | ダラツムマブ薬物コンジュゲートおよびその調製 |
| AU2024304180A1 (en) | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| WO2025185617A1 (en) * | 2024-03-05 | 2025-09-12 | Hutchmed Limited | Linker, antibody-drug conjugate and use thereof |
| WO2025264533A1 (en) | 2024-06-17 | 2025-12-26 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins |
| CN120713867A (zh) * | 2025-08-20 | 2025-09-30 | 中国人民解放军西部战区总医院 | 一种微管蛋白破坏剂二聚体与铜死亡药物联用的纳米颗粒、其制备方法及用途 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| DK0871490T3 (da) | 1995-12-22 | 2003-07-07 | Bristol Myers Squibb Co | Forgrenede hydrazonlinkere |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| JP5356648B2 (ja) | 2003-02-20 | 2013-12-04 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ７０抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用 |
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| JP2008521828A (ja) * | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| DK1912677T3 (da) * | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| MX347954B (es) | 2010-09-29 | 2017-05-19 | Agensys Inc | Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 191p4d12. |
| EP3581206B8 (en) * | 2010-10-22 | 2025-02-19 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| BR112013027119A8 (pt) | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | novos conjugados ligante-droga (adcs) e uso dos mesmos |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| NZ758049A (en) | 2013-10-15 | 2024-03-22 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
| SG11201609372UA (en) * | 2014-05-22 | 2016-12-29 | Synthon Biopharmaceuticals Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
| FI3900742T3 (fi) | 2014-09-11 | 2024-08-16 | Seagen Inc | Tertiääristä amiinia sisältävien lääkeaineiden kohdennettu antaminen |
| BR112017023862A2 (pt) * | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| KR20180090290A (ko) | 2015-12-04 | 2018-08-10 | 시애틀 지네틱스, 인크. | 사차화 튜불리신 화합물들의 컨쥬게이트들 |
| WO2018031408A1 (en) * | 2016-08-11 | 2018-02-15 | Immunomedics, Inc. | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS |
-
2019
- 2019-03-22 TW TW108109929A patent/TW202003047A/zh unknown
- 2019-03-22 CN CN201980033040.7A patent/CN112189020A/zh active Pending
- 2019-03-22 MA MA052135A patent/MA52135A/fr unknown
- 2019-03-22 CA CA3093731A patent/CA3093731A1/en active Pending
- 2019-03-22 SG SG11202009264WA patent/SG11202009264WA/en unknown
- 2019-03-22 MX MX2020009842A patent/MX2020009842A/es unknown
- 2019-03-22 EP EP19715720.9A patent/EP3768714A1/en active Pending
- 2019-03-22 KR KR1020207030320A patent/KR20200135841A/ko not_active Ceased
- 2019-03-22 WO PCT/US2019/023516 patent/WO2019183438A1/en not_active Ceased
- 2019-03-22 JP JP2020550674A patent/JP2021518397A/ja active Pending
- 2019-03-22 BR BR112020018948-0A patent/BR112020018948A2/pt not_active Application Discontinuation
- 2019-03-22 US US16/362,125 patent/US20190290775A1/en not_active Abandoned
- 2019-03-22 AU AU2019240403A patent/AU2019240403A1/en not_active Abandoned
-
2020
- 2020-09-14 IL IL277338A patent/IL277338A/en unknown
-
2022
- 2022-07-21 US US17/870,749 patent/US20230110128A1/en not_active Abandoned
-
2024
- 2024-03-28 JP JP2024052953A patent/JP2024075771A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518397A5 (https=) | ||
| Ab et al. | IMGN853, a folate receptor-α (FRα)–targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors | |
| AU2019320336B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| JP7386208B2 (ja) | 抗ｆｏｌｒ１免疫抱合体投薬レジメン | |
| Matsuzaki et al. | Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer | |
| JP2019532056A5 (https=) | ||
| Klute et al. | Microtubule inhibitor-based antibody–drug conjugates for cancer therapy | |
| JP2024075771A (ja) | 固形腫瘍を治療するためのチューブリン破壊剤を含む抗体薬物コンジュゲートの使用 | |
| JP2017510559A5 (https=) | ||
| CN108348608B (zh) | 抗5t4抗体和抗体-药物缀合物 | |
| JP7547205B2 (ja) | 抗ｈｅｒ２バイパラトピック抗体－薬物コンジュゲート及び使用方法 | |
| JP2018520091A5 (https=) | ||
| Hicks et al. | The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models | |
| FI3930847T3 (fi) | Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä | |
| CN108136015A (zh) | 抗dll3抗体药物缀合物以及使用方法 | |
| HRP20170743T1 (hr) | Anti-ceacam5 protutijela i njihova uporaba | |
| HK1255234A1 (zh) | 经半胱氨酸取代的免疫球蛋白 | |
| JP2018502902A (ja) | ピロロベンゾジアゼピン−抗体コンジュゲート | |
| Scott et al. | A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen | |
| JP2018523471A5 (https=) | ||
| Crépin et al. | Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas | |
| Hartimath et al. | Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft | |
| Shinmi et al. | Novel anticarcinoembryonic antigen antibody–drug conjugate has antitumor activity in the existence of soluble antigen | |
| Krug et al. | Targeting Lewis Y (LeY) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels | |
| MX2025006057A (es) | Conjugados anticuerpo-farmaco anti-cea y metodos de uso |